Clinical Trials in Maryland

Showing 8161-8180 of 23,284 trials

Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation

NCT03225157

Background: Cisplatin is a chemotherapy drug. It is used to treat head and neck squamous cell carcinoma (HNSCC) and other cancers. It can cause hearing loss for some people. It is not known how many people will get hearing loss from cisplatin. It is also not known what other factors might influence who gets hearing loss. Factors could include age, sex, noise exposure, and other drugs the person is taking. Statins are drugs used to lower cholesterol. Statins may also reduce cisplatin-induced hearing loss. Objectives: To see if statins reduce hearing loss in people getting cisplatin therapy to treat HNSCC. To find out how many people taking cisplatin get hearing loss from it. To find out if other factors might influence whether cisplatin causes hearing loss. Eligibility: People ages 18 and older who are getting treatment with cisplatin for HNSCC Design: Participants will be screened with a review of their medical records. Participants will have 3 visits. These will be before the onset of cisplatin therapy, at about 4 weeks after they finish therapy, and about 6 months after they finish therapy. Each visit will include: Medication history Audiogram/hearing tests. Participants will wear headphones and indicate when they hear different sounds. Questions about their noise exposure history and whether they have ringing in the ears

Head and Neck NeoplasmsHearing DisorderHyperlipidemia

National Institute on Deafness and Other Communication Disorders (NIDCD)32 participantsStarted Nov 2017

Bethesda, Maryland, United States • Bethesda, Maryland, United States

COMPLETEDNA19 miles

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

NCT01812447

EMPROVE is a multicenter, prospective, randomized, controlled study designed to evaluate the safety and long-term effectiveness of the Spiration Valve System in patients with emphysema. Patients appropriate for the EMPROVE study are those who are currently on medical treatment but still symptomatic. EMPROVE also accepts α-1 antitrypsin deficiency patients.

Emphysema

Olympus Corporation of the Americas172 participantsStarted Jun 2013

Fort Smith, Arkansas, United States • Riverside, California, United States • San Diego, California, United States +31 more locations

Hearing Loss and the Effects of Statin Drugs in People With Head and Neck Squamous Cell Carcinoma Treated With Cisplatin Chemoradiation

Evaluation of the Spiration® Valve System for Emphysema to Improve Lung Function

Find Trials by Condition in Maryland

Treatment of Refractory BK Infections With Related Donor BK Specific Cytotoxic T-cells (CTLs)

Safety and Efficacy of Emixustat in Stargardt Disease

Surgical Site Infection and Antibiotic Use Study

A Trial to Evaluate Two Schedules of MS275 in Combination With 5AC in Elderly Patients With Acute Myeloid Leukemia (AML)

Apremilast as a Direct Treatment for Mild-to-moderate Plaque Psoriasis Versus Placebo: an Analysis of Clinical Safety and Efficacy

Predictors of Severe COVID-19 Outcomes

IN.PACT™ AV Access IDE Study

A Study of B + L Ophthalmic Viscosurgical Device (OVD) CVisc50

A Study to Evaluate Ketamine for the Treatment of Rett Syndrome

Clinical Trial Multi-analyte Blood Test

Comparison of Aerosol Delivery of Infasurf to Usual Care in Spontaneously Breathing RDS Patients

Brexpiprazole in Treatment of Children and Adolescents With Irritability Associated With Autism Spectrum Disorder for Subjects That Have Completed Participation in 331-201-00148

Safety, Tolerability, and Efficacy of Arbaclofen in 16p11.2 Deletion

Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders

Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia

Safety and Pharmacokinetics of AT-007 in Healthy Subjects and in Adult Subjects With Classic Galactosemia

Retrospective Study of Glucose Monitoring for Glycemic Control in Patients With GSDIa

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)